TLR2 and synucleinopathy: A study in a preclinical model of synucleinopathies has shown that the administration of anti-TLR2 improves the neuropathology and behavioral outcome by limiting neurons-to-astrocytes transmission of α-Syn, thus boosting new hopes for future clinical applications of TLR2 antagonists in the field of PD [109].